Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

A
ESMO-MCBS v1.1
Scorecard version: 1

Indication details

Tumour Type
Gastrointestinal Cancers
Tumour Sub-type
Pancreatic cancer
Tumour stage
Early
Control Arm
Gemcitabine
Treatment Setting
Resected pancreatic ductal adenocarcinoma
Trial Name
PRODIGE 24/CCTG PA. 6 trial

Primary Outcome(s)

Primary Outcome(s)
OS
Form(s)
Form 1

Outcome Data

OS Control
35.0 months
OS Gain
19.4 months 3-year survival gain 14.8%
OS HR
0.64 (0.48-0.86)
Toxicity Comment
Increased acute toxicity

Final Score (after adjustments)

Final curative score
A
Release date
14.05.2019

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.